Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to -$92.0 million.

  • Novartis Ag's Other Non Operating Income fell 37878.79% to -$92.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$136.0 million, marking a year-over-year decrease of 19714.29%. This contributed to the annual value of -$136.0 million for FY2025, which is 19714.29% down from last year.
  • Novartis Ag's Other Non Operating Income amounted to -$92.0 million in Q4 2025, which was down 37878.79% from -$20.0 million recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Other Non Operating Income registered a high of $104.0 million during Q1 2023, and its lowest value of -$92.0 million during Q4 2025.
  • In the last 5 years, Novartis Ag's Other Non Operating Income had a median value of $15.5 million in 2022 and averaged $8.9 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 43125.0% in 2023, then crashed by 37878.79% in 2025.
  • Over the past 5 years, Novartis Ag's Other Non Operating Income (Quarter) stood at -$26.0 million in 2021, then surged by 192.31% to $24.0 million in 2022, then dropped by 25.0% to $18.0 million in 2023, then skyrocketed by 83.33% to $33.0 million in 2024, then plummeted by 378.79% to -$92.0 million in 2025.
  • Its last three reported values are -$92.0 million in Q4 2025, -$20.0 million for Q3 2025, and -$41.0 million during Q2 2025.